Back to User profile » Dr Adriano Lazzarin

Papers published by Dr Adriano Lazzarin:


Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A

Drug Design, Development and Therapy 2022, 16:3737-3738

Published Date: 27 October 2022

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice

Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A

Drug Design, Development and Therapy 2022, 16:1975-1982

Published Date: 27 June 2022

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Spagnuolo V, Galli L, Poli A, Bigoloni A, Fumagalli L, Gianotti N, Nozza S, Ferrari D, Locatelli M, Lazzarin A, Castagna A

Drug Design, Development and Therapy 2019, 13:477-479

Published Date: 24 January 2019

Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service

Restelli U, Andreoni M, Antinori A, Bonfanti M, Di Perri G, Galli M, Lazzarin A, Rizzardini G, Croce D

ClinicoEconomics and Outcomes Research 2014, 6:409-414

Published Date: 23 September 2014

Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting

Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A

Therapeutics and Clinical Risk Management 2014, 10:9-15

Published Date: 18 December 2013